HBM Holdings Limited (FRA:6XY)

Market Cap	986.96M +30.4%
Revenue (ttm)	134.55M +314.6%
Net Income	77.79M +3,187.7%
EPS	0.09 +2,958.9%
Shares Out	n/a
PE Ratio	12.69
Forward PE	18.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.100
Previous Close	1.170
Day's Range	1.100 - 1.130
52-Week Range	0.800 - 2.140
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 272
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XY

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD